Intravenous Immunoglobulin Does Not Improve Clinical Outcomes Compared With Tocilizumab in Severe COVID-19

Source: Pharmacy Times articles

A study reveals IVIG treatment shows no significant benefits over tocilizumab for severe COVID-19, highlighting higher adverse events and costs.
Read More